Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Detalles Bibliográficos
Autores principales: Parikh, Ravi B., Hubbard, Rebecca A., Wang, Erkuan, Royce, Trevor J., Cohen, Aaron B., Clark, Amy S., Mamtani, Ronac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951100/
https://www.ncbi.nlm.nih.gov/pubmed/36821118
http://dx.doi.org/10.1001/jamaoncol.2022.7770
Descripción
Sumario:This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Ejemplares similares